DBVT | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 10%

Performance

5 Days

-7.74%

1 Month

401.65%

3 Months

343.80%

6 Months

223.40%

1 Year

60.00%

2 Year

5.56%

Key data

Stock price

$3.05

P/E Ratio

0.00

DAY RANGE

$3.18 - $3.30

EPS

$0.00

52 WEEK RANGE

$0.49 - $4.50

52 WEEK CHANGE

$53.54

MARKET CAP

86.849 M

YIELD

N/A

SHARES OUTSTANDING

96.499 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

10/29/2024

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$52,142

AVERAGE 30 VOLUME

$401,397

Company detail

CEO: Daniel Tassé
Region: US
Website: dbv-technologies.com
Employees: 80
IPO year: -

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

DBV Technologies S.A. engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus.

DBVT - DBV Technologies S.A.